U.S. Markets close in 5 hrs 48 mins

Targovax ASA (TRVXO.OL)

Oslo - Oslo Delayed Price. Currency in NOK
Add to watchlist
9.880.00 (0.00%)
As of 4:15PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.88
Open10.26
Bid0.00 x N/A
Ask10.08 x N/A
Day's Range9.88 - 9.88
52 Week Range9.88 - 9.88
Volume225
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital

    The board of directors of Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") has resolved to increase the share capital of the Company following the completion of an exercise period for vested share options under the Company's long-term incentive program for employees. The exercise period for the LTI program commenced on 19 February 2021 at 10:00 hours (CET) and ended on 1 March 2021 at 10:00 hours (CET).

  • Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up
    PR Newswire

    Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up

    Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces 21-month follow-up data from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma (MPM).

  • PR Newswire

    Targovax receives Fast-Track designation for ONCOS-102

    Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.